Progenics Pharma Revenue, Profits - PGNX Quarterly Income Statement

Add to My Stocks
$8.36 $0.09 (1.09%) PGNX stock closing price Mar 21, 2018 (Closing)

Fundamental analysis of PGNX stock involves analyzing its financial statements, apart from checking the Progenics Pharma stock price. The key financial statements of a company are the income statement, the balance sheet and the cash flow statement. The income statement for PGNX which shows a YOY revenue decline of -2.53% is specific to a period of time. Investors typically check YoY or QoQ revenue growth. One also needs to look at Progenics Pharma assets, operating expenses and Progenics Pharma free cash flow. The Progenics Pharma profit and loss statement shows revenue of $2.7M for 2017 Q3. Revenue has decreased by -2.53% QoQ for PGNX stock.

View and download details of revenue and profits for Progenics Pharma for latest & last 40 quarters.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q42015 Q3
Progenics Pharma Revenues or Net Sales
Cost Of Goods Sold (COGS)---------
Progenics Pharma Gross Profit
Research & Development Expense10.34M11.29M10M10.62M9.82M7.98M9.14M7.96M7.04M
Selling General & Admin Expense6.65M7.03M7.59M-1.27M7.82M6.19M6.01M4.87M4.23M
Income Before Depreciation Depletion Amortization-14.3M-15.56M-15.25M-4.68M36.2M-5.71M-12.71M-7.72M-9.88M
Depreciation Depletion Amortization--------0.38M-
Non Operating Income-1.04M-1.07M-1.1M-0.19M-----
Interest Expense---------
Progenics Pharma Pretax Income
Provision for Income Taxes---1.84M----0.13M-
Investment Gains Losses---------
Other Income---------
Income Before Extraordinaries & Disc Operations-15.35M-16.64M-16.36M-7.2M36.3M-5.64M-12.66M-7.15M-10.01M
Extraordinary Items & Discontinued Operations---------
Progenics Pharma Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS70.27M70.2M70.2M70.1M70.3M69.95M69.95M69.87M69.71M
Average Shares used to compute Basic EPS70.27M70.2M70.2M70.1M70.01M69.95M69.95M69.87M69.71M
Income Before Nonrecurring Items-15.35M-16.64M-16.36M-7.2M36.3M-5.64M-12.66M-7.15M-10.01M
Income from Nonrecurring Items---------
Progenics Pharma Earnings Per Share Basic Net
Progenics Pharma Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.22-0.24-0.23-0.100.52-0.08-0.18-0.10-0.14
Preferred Dividends Acc Pd---------
Dividends Common0.00--------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Progenics Pharma stock analysis involves checking at least a few of the important things like:

  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that PGNX stock has a topline or revenue of $2.7M for 2017 Q3 as per this Progenics Pharma revenue chart. Investors look for stocks with a growing top line.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. PGNX stock had a healthy bottom line growth.

The income statement is also called the profit and loss statement. Apart from the PGNX income statement, one can check the Progenics Pharma historical stock prices to check how the price has moved with time.

Progenics Pharma Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
Dividend Yield